The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2022 | Gastric cancer updates at ESMO 2022
Kohei Shitara, MD, National Cancer Center Hospital East, Kashiwa, Japan, provides an overview of the latest news in gastric cancers from the European Society for Medical Oncology (ESMO) 2022 Congress, including updates on the use of trastuzumab deruxtecan, as well as the role of upfront chemotherapy. Dr Kohei anticipates results from Claudin 18.2 targeting therapies, as well as FGFR-targeting approaches. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
